{
    "clinical_study": {
        "@rank": "109159", 
        "arm_group": [
            {
                "arm_group_label": "Arm A - active treatment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm B - placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The most notable tolerability finding from these multiple dosing studies has been the\n      occurrence of mild to moderate rash at doses of 450 mg BID and 600 mg BID.  Based upon this\n      finding, the current four week study is designed to examine whether a slow titration regimen\n      up to a lower maintenance dose of 450 mg BID is able to reduce the incidence of rash."
        }, 
        "brief_title": "Safety And Tolerability Study Of BID Titration Scheme With PF-05089771", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects of non-child bearing potential between the ages\n             of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant\n             abnormalities identified by a detailed medical history, full physical examination,\n             including blood pressure and pulse rate\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal (ie, recurrent\n             nephrolitisis), endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,\n             psychiatric, neurologic, or allergic disease (including drug allergies, but excluding\n             untreated, asymptomatic, seasonal allergies at time of dosing).\n\n          -  History of, or presence of allergic skin reactions or active skin disease (except for\n             subjects with acne who may be included in the study) at the time of screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772264", 
            "org_study_id": "B3291018"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A - active treatment", 
                "description": "titration from 150mg BID to 450mg BID", 
                "intervention_name": "PF-05089771", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B - placebo", 
                "description": "matched placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 8, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3291018&StudyName=Safety%20And%20Tolerability%20Study%20Of%20BID%20Titration%20Scheme%20With%20PF-05089771"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Investigator And Subject Blinded, Sponsor Open, Randomized, Placebo Controlled, Multiple Dose Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-05089771 In Healthy Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Area Under the Curve from Time Zero to end of dosing interval (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "12h"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "12h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772264"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Minimum Observed Plasma Trough Concentration (Cmin)", 
            "safety_issue": "No", 
            "time_frame": "12h post dose"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}